INTRODUCTION: Given the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of particularly vulnerable individuals has gained increasing attention during the course of the pandemic. METHODS: We performed a 1-year follow-up study of 51 ocrelizumab-treated patients with multiple sclerosis (OCR-pwMS) who received COVID-19 vaccination in 2021. We retrospectively identified 37 additional OCR-pwMS, 42 pwMS receiving natalizumab, 27 pwMS receiving sphingosine 1-phosphate receptor modulators, 59 pwMS without a disease-modifying therapy, and 61 controls without MS (HC). In OCR-pwMS, anti-SARS-CoV-2(S)-antibody titers were measured prior to the first and after the second, third, and fourth vaccine doses (pv2/3/4). The SARS-CoV-2-specific T cell response was analyzed pv2. SARS-CoV-2 infection status, COVID-19 disease severity, and vaccination-related adverse events were assessed in all pwMS and HC. RESULTS: We found a pronounced and increasing anti-SARS-CoV-2(S)-antibody response after COVID-19 booster vaccinations in OCR-pwMS (pv2: 30.4%, pv3: 56.5%, and pv4 90.0% were antibody positive). More than one third of OCR-pwMS without detectable antibodies pv2 developed positive antibodies pv3. 23.5% of OCR-pwMS had a confirmed SARS-CoV-2 infection, of which 84.2% were symptomatic. Infection rates were comparable between OCR-pwMS and control groups. None of the pwMS had severe COVID-19. An attenuated humoral immune response was not associated with a higher risk of SARS-CoV-2 infection. DISCUSSION: Additional COVID-19 vaccinations can boost the humoral immune response in OCR-pwMS and improve clinical protection against COVID-19. Vaccines effectively protect even OCR-pwMS without a detectable COVID-19 specific humoral immune response, indicating compensatory, e.g., T cell-mediated immunological mechanisms.

Brain and Mind Center University of Sydney Sydney NSW Australia

Department of Neurology Center for Neurology and Neuropsychiatry LVR Klinikum Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Czechia

See more in PubMed

Räuber S, Korsen M, Huntemann N, Rolfes L, Müntefering T, Dobelmann V, et al. . Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. J Neurol Neurosurg Psychiatr (2022) 93:978–985. doi: 10.1136/jnnp-2021-328197 PubMed DOI PMC

Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, et al. . Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol (2021) 78:1510–1514. doi: 10.1001/jamaneurol.2021.3599 PubMed DOI PMC

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord (2021) 14:17562864211012836. doi: 10.1177/17562864211012835 PubMed DOI PMC

Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med (2021) 27:1990–2001. doi: 10.1038/s41591-021-01507-2 PubMed DOI PMC

Alfonso-Dunn R, Lin J, Kirschner V, Lei J, Feuer G, Malin M, et al. . Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving b-cell depleting therapies. Front Immunol (2022) 13:926318. doi: 10.3389/fimmu.2022.926318 PubMed DOI PMC

Capuano R, Bisecco A, Conte M, Donnarumma G, Altieri M, Grimaldi E, et al. . Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Mult Scler Relat Disord (2022) 60:103724. doi: 10.1016/j.msard.2022.103724 PubMed DOI PMC

König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, et al. . Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol (2022) 79:307–9. doi: 10.1001/jamaneurol.2021.5109 PubMed DOI PMC

Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, et al. . Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol (2022) 79:399–404. doi: 10.1001/jamaneurol.2022.0245 PubMed DOI PMC

Wallach AI, Schiebel M, Picone MA. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies. Mult Scler Relat Disord (2022) 63:103856. doi: 10.1016/j.msard.2022.103856 PubMed DOI PMC

Maglione A, Morra M, Meroni R, Matta M, Clerico M, Rolla S. Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies. Mult Scler Relat Disord (2022) 61:103776. doi: 10.1016/j.msard.2022.103776 PubMed DOI PMC

Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, et al. . Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Mult Scler Relat Disord (2022) 64:103937. doi: 10.1016/j.msard.2022.103937 PubMed DOI PMC

Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, et al. . Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Mult Scler Relat Disord (2022) 60:103729. doi: 10.1016/j.msard.2022.103729 PubMed DOI PMC

Paybast S, Hejazi SA, Molavi P, Habibi MA, Naser Moghadasi A. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in qom province, Iran. Mult Scler Relat Disord (2022) 60:103712. doi: 10.1016/j.msard.2022.103712 PubMed DOI PMC

Brunn JA, Dunietz GL, Romeo AR, Braley TJ. SARS-CoV-2 infection and vaccination outcomes in multiple sclerosis. Neurol Clin Pract (2022) 12:e14–21. doi: 10.1212/CPJ.0000000000001164 PubMed DOI PMC

Garjani A, Patel S, Bharkhada D, Rashid W, Coles A, Law GR, et al. . Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord (2022) 57:103458. doi: 10.1016/j.msard.2021.103458 PubMed DOI PMC

Zanetta C, Rocca MA, Filippi M. Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients. Expert Rev Clin Immunol (2022) 18:495– 512. doi: 10.1080/1744666X.2022.2064845 PubMed DOI

Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, et al. . Prolonged SARS-CoV-2 illness in a patient receiving ocrelizumab for multiple sclerosis. Open Forum Infect Dis (2021) 8:ofab176. doi: 10.1093/ofid/ofab176 PubMed DOI PMC

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. . Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol (2021) 89:780–9. doi: 10.1002/ana.26028 PubMed DOI PMC

van Kempen ZLE, Kummer LYL, Wieske L, Rispens T, Eftimov F, Killestein J. Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab. Neuroimmunol Rep (2022) 2:100072. doi: 10.1016/j.nerep.2022.100072 DOI

Jakimovski D, Zakalik K, Awan S, Kavak KS, Pennington P, Hojnacki D, et al. . COVID-19 vaccination in multiple sclerosis and inflammatory diseases: Effects from disease-modifying therapy, long-term seroprevalence and breakthrough infections. Vaccines (Basel) (2022) 10:695. doi: 10.3390/vaccines10050695 PubMed DOI PMC

Ponzano M, Schiavetti I, Bovis F, Landi D, Carmisciano L, De Rossi N, et al. . A multiparametric score for assessing the individual risk of severe covid-19 among patients with multiple sclerosis. Mult Scler Relat Disord (2022) 63:103909. doi: 10.1016/j.msard.2022.103909 PubMed DOI PMC

Schiavetti I, Cordioli C, Stromillo ML, Teresa Ferrò M, Laroni A, Cocco E, et al. . Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler (2022), 28:2106–2111. doi: 10.1177/13524585221102918 PubMed DOI

Cross AH, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, et al. . COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. Neurol Ther (2022) 11:741–758. doi: 10.1007/s40120-022-00341-z PubMed DOI PMC

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol (2018) 17:162–73. doi: 10.1016/S1474-4422(17)30470-2 PubMed DOI

Robert Koch-Institut . Anzahl und anteile von VOC und VOI in deutschland . Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/VOC_VOI_Tabelle.html (Accessed August 26, 2022).

Geng J, Yu X, Bao H, Feng Z, Yuan X, Zhang J, et al. . Chronic diseases as a predictor for severity and mortality of COVID-19: A systematic review with cumulative meta-analysis. Front Med (Lausanne) (2021) 8:588013. doi: 10.3389/fmed.2021.588013 PubMed DOI PMC

Carmona-Pírez J, Gimeno-Miguel A, Bliek-Bueno K, Poblador-Plou B, Díez-Manglano J, Ioakeim-Skoufa I, et al. . Identifying multimorbidity profiles associated with COVID-19 severity in chronic patients using network analysis in the PRECOVID study. Sci Rep (2022) 12:2831. doi: 10.1038/s41598-022-06838-9 PubMed DOI PMC

Milo R, Staun-Ram E, Karussis D, Karni A, Hellmann MA, Bar-Haim E, et al. . Israeli Neuroimmunology study group on COVID-19 vaccination in multiple sclerosis. humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis: An Israeli multi-center experience following 3 vaccine doses. Front Immunol (2022) 13:868915. doi: 10.3389/fimmu.2022.868915 PubMed DOI PMC

Satyanarayan S, Safi N, Sorets T, Filomena S, Zhang Y, Klineova S, et al. . Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Mult Scler Relat Disord (2022) 62:103737. doi: 10.1016/j.msard.2022.103737 PubMed DOI PMC

Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. . Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol (2021) 78:1529–1531. doi: 10.1001/jamaneurol.2021.3609 PubMed DOI PMC

Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regeneration of b cell subsets after transient b cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum (2006) 54:2377–86. doi: 10.1002/art.22019 PubMed DOI

Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol (2015) 15:160–71. doi: 10.1038/nri3795 PubMed DOI

Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, et al. . Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm (2021) 8:e1035. doi: 10.1212/NXI.0000000000001035 PubMed DOI PMC

Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol (2022) 23:186–93. doi: 10.1038/s41590-021-01122-w PubMed DOI

Kingstad-Bakke B, Lee W, Chandrasekar SS, Gasper DJ, Salas-Quinchucua C, Cleven T, et al. . Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci USA (2022) 119:e2118312119. doi: 10.1073/pnas.2118312119 PubMed DOI PMC

Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, et al. . Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the delta and the omicron waves in Italy. EBioMedicine (2022) 80:104042. doi: 10.1016/j.ebiom.2022.104042 PubMed DOI PMC

Centers of Disease Control and Prevention . Risk for COVID-19 infection, hospitalization, and death by age group . Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html (Accessed June 13, 2022).

Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. PLos One (2022) 17:e0268119. doi: 10.1371/journal.pone.0268119 PubMed DOI PMC

Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. . Male Sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun (2020) 11:6317. doi: 10.1038/s41467-020-19741-6 PubMed DOI PMC

Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol (2021) 28:3742–8. doi: 10.1111/ene.15028 PubMed DOI PMC

Di Filippo M, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, et al. . mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatr (2022) 93:448–50. doi: 10.1136/jnnp-2021-327200 PubMed DOI

Hoffmann MA, Wieler HJ, Enders P, Buchholz H-G, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines (Basel) (2021) 9:911. doi: 10.3390/vaccines9080911 PubMed DOI PMC

Al-Midfai Y, Kujundzic W, Uppal S, Oakes D, Giezy S. Acute multiple sclerosis exacerbation after vaccination with the Johnson & Johnson COVID-19 vaccine: Novel presentation and first documented case report. Cureus (2022) 14:e24017. doi: 10.7759/cureus.24017 PubMed DOI PMC

Quintanilla-Bordás C, Gascón-Gimenez F, Alcalá C, Payá M, Mallada J, Silla R, et al. . Case report: Exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: A case series. Front Neurol (2022) 13:897275. doi: 10.3389/fneur.2022.897275 PubMed DOI PMC